These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 11190365)

  • 41. Milnacipran-associated urinary retention: a case report.
    Aggarwal A; Khandelwal A; Jiloha RC
    J Clin Psychopharmacol; 2010 Oct; 30(5):641. PubMed ID: 20841968
    [No Abstract]   [Full Text] [Related]  

  • 42. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
    Baldwin D; Bridgman K; Buis C
    J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Therapy refractory depressive episode in bipolar disorder caused by primary hyperparathyroidism].
    Drach LM
    Psychiatr Prax; 2001 Mar; 28(2):100-1. PubMed ID: 11305157
    [No Abstract]   [Full Text] [Related]  

  • 44. [Pharmacotherapy of children with depressive disorders].
    Denizot H; Laporte F; Llorca PM
    Arch Pediatr; 2009 Aug; 16(8):1208-12. PubMed ID: 19586758
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
    Akkaya C; Sivrioglu EY; Akgoz S; Eker SS; Kirli S
    Hum Psychopharmacol; 2006 Jul; 21(5):337-45. PubMed ID: 16856215
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Acute dystonia induced by fluoxetine].
    Vaamonde J; del Real MA; Ibáñez R; Gudín M
    Neurologia; 1996 May; 11(5):197. PubMed ID: 8845186
    [No Abstract]   [Full Text] [Related]  

  • 47. Open trials in psychiatry: comments on article by Uchida et Al.
    Magalhães PV
    J Clin Psychopharmacol; 2007 Jun; 27(3):318; author reply 318-9. PubMed ID: 17502793
    [No Abstract]   [Full Text] [Related]  

  • 48. The modern pharmacopoeia: a return to depressive realism?
    Goldberg JF
    Bipolar Disord; 2008 Dec; 10(8):969-72. PubMed ID: 19594511
    [No Abstract]   [Full Text] [Related]  

  • 49. Profound weight loss associated with reboxetine use in a 44-year-old woman.
    Lu TY; Kupa A; Easterbrook G; Mangoni AA
    Br J Clin Pharmacol; 2005 Aug; 60(2):218-20. PubMed ID: 16042676
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
    Papakostas GI; McGrath P; Stewart J; Charles D; Chen Y; Mischoulon D; Dording C; Fava M
    Psychiatry Res; 2008 Oct; 161(1):116-20. PubMed ID: 18755514
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Therapy resistant major depression: improvement of symptomatology after combining antidepressants with Tianeptine (Stablon)].
    Niederhofer H
    Psychiatr Prax; 2003 May; 30(4):221-2. PubMed ID: 12768529
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antidepressant Prescription in the Geriatric Population: A Teachable Moment.
    Das A; Maiti A; Sinha S
    JAMA Intern Med; 2016 Nov; 176(11):1608-1609. PubMed ID: 27668672
    [No Abstract]   [Full Text] [Related]  

  • 53. Finding studies on reboxetine: a tale of hide and seek.
    Wieseler B; McGauran N; Kaiser T
    BMJ; 2010 Oct; 341():c4942. PubMed ID: 20940211
    [No Abstract]   [Full Text] [Related]  

  • 54. Reboxetine-induced spontaneous ejaculation.
    O'Flynn R; Michael A
    Br J Psychiatry; 2000 Dec; 177():567-8. PubMed ID: 11102344
    [No Abstract]   [Full Text] [Related]  

  • 55. Reboxetine-induced hypomania.
    Vieta E; Colom F; Martínez-Arán A; Reinares M; Benabarre A; Corbella B; Gastó C
    J Clin Psychiatry; 2001 Aug; 62(8):655-6. PubMed ID: 11561941
    [No Abstract]   [Full Text] [Related]  

  • 56. Mirtazapine-associated urinary retention.
    Oulis P; Leonardos A; Koulouris GC; Konstantakopoulos G
    J Neuropsychiatry Clin Neurosci; 2010; 22(3):352o.e21-352.e22. PubMed ID: 20686159
    [No Abstract]   [Full Text] [Related]  

  • 57. Novel treatments for major depressive disorder.
    Lydiard RB
    CNS Spectr; 2009 Mar; 14(3 Suppl 5):11-3. PubMed ID: 19407718
    [No Abstract]   [Full Text] [Related]  

  • 58. [A comparative study of befol pharmacokinetics in experimental animals and man].
    Rodionov AP; Ignatova NA; Kushnarev VV; Muzychenko AP
    Farmakol Toksikol; 1990; 53(2):62-3. PubMed ID: 2369959
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effects of reboxetine on human sleep architecture in depression: preliminary results.
    Farina B; Della Marca G; Mennuni G; Mazza S; De Risio S; Di Giannantonio M
    J Affect Disord; 2002 Sep; 71(1-3):273-5. PubMed ID: 12167528
    [No Abstract]   [Full Text] [Related]  

  • 60. Biological markers and depression.
    Mackey I
    Adv NPs PAs; 2013 Aug; 4(8):29-30. PubMed ID: 23943973
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.